Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 3
1958 3
1961 1
1962 1
1963 1
1966 2
1967 1
1968 4
1970 2
1974 3
1976 1
1978 4
1979 2
1980 3
1981 4
1982 4
1983 5
1984 2
1985 4
1986 4
1987 1
1988 3
1989 7
1990 4
1991 9
1992 5
1993 2
1994 3
1995 3
1996 1
1997 3
1998 4
1999 2
2000 1
2001 2
2003 1
2006 2
2008 3
2011 2
2012 2
2013 1
2014 1
2015 2
2016 1
2017 2
2018 3
2019 3
2020 2
2021 4
2022 8
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group. Bouhnik Y, et al. Among authors: picon l. Gut. 2018 Jan;67(1):53-60. doi: 10.1136/gutjnl-2016-312581. Epub 2017 Jan 24. Gut. 2018. PMID: 28119352 Free PMC article.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Among authors: picon l. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
[Guidelines for esophageal pH-monitoring in adults].
Picon L, Bruley Des Varannes S; Groupe de Travail sur les Recommandations pour lapratique de la pHmétrie esophagienne. Picon L, et al. Gastroenterol Clin Biol. 2000 Oct;24(10):931-43. Gastroenterol Clin Biol. 2000. PMID: 11084431 Free article. Review. French. No abstract available.
Hormonal control of fetal development and metabolism.
Jost A, Picon L. Jost A, et al. Among authors: picon l. Adv Metab Disord. 1970;4:123-84. doi: 10.1016/b978-0-12-027304-1.50010-7. Adv Metab Disord. 1970. PMID: 4922838 Review. No abstract available.
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Guillo L, Savoye G, Amiot A, Gilletta C, Nachury M, Dib N, Bourreille A, Roblin X, Caillo L, Allez M, Picon L, Hébuterne X, Seksik P, Chupin A, Buisson A, Brixi H, Altwegg R, Simon M, Amil M, Laharie D, Bouguen G, Serrero M, Elgharabawy Y, Peyrin-Biroulet L; EXTRA Study Group. Guillo L, et al. Among authors: picon l. Clin Transl Gastroenterol. 2023 Dec 1;14(12):e00607. doi: 10.14309/ctg.0000000000000607. Clin Transl Gastroenterol. 2023. PMID: 37523417 Free PMC article.
138 results